{
    "clinical_study": {
        "@rank": "100666", 
        "arm_group": [
            {
                "arm_group_label": "Melatonin", 
                "arm_group_type": "Active Comparator", 
                "description": "Participants receive 3 mgs of time-release melatonin 1-2 hours prior to bedtime."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Participants receive a placebo identical to the time-release melatonin and are instructed to take it 1-2 hours prior to bedtime."
            }
        ], 
        "brief_summary": {
            "textblock": "Primary objective:\n\n        1. To examine the efficacy of melatonin treatment on neurocognitive functioning in adult\n           survivors of childhood cancer.\n\n      Secondary objectives:\n\n        1. To evaluate the efficacy of melatonin treatment on delayed sleep onset latency in\n           long-term childhood cancer survivors.\n\n        2. To investigate whether improvement in sleep onset latency due to melatonin treatment is\n           associated with neurocognitive improvement in long-term childhood cancer survivors.\n\n      This study is a randomized double-blind placebo controlled trial of time release melatonin\n      for adult survivors of childhood cancer who demonstrate impaired neurocognitive functioning\n      and/or difficulty falling asleep."
        }, 
        "brief_title": "Melatonin Intervention For Neurocognitive Deficits in the St. Jude Lifetime Cohort", 
        "completion_date": {
            "#text": "January 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Cancer Malignancies", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "All participants undergo a general neurocognitive evaluation at baseline and 6-month\n      follow-up, focused on assessment of intelligence, academic skills, attention, processing\n      speed, memory and executive functions.\n\n      Sleep parameters using self-report and actigraphy will be assessed at three time points\n      during the study: Baseline, 3-months, and 6-months.\n\n      Participants will be divided into 3 mutually exclusive groups:\n\n        -  Cohort 1:  Participant has neurocognitive impairment defined as performance on at least\n           one measure of attention, memory, and/or executive functioning at or below the 10th\n           percentile, AND is absent of delayed sleep onset latency defined as an inability to\n           fall asleep within 30 minutes less than once a week during the past month.\n\n        -  Cohort 2:  Participant has neurocognitive impairment defined as performance on at least\n           one measure of attention, memory, and/or executive functioning at or below the 10th\n           percentile, AND has delayed sleep onset latency defined as self-report of an inability\n           to fall asleep within 30 minutes at least once a week during the past month.\n\n        -  Cohort 3:  Participant is absent of neurocognitive impairment defined as performance\n           >10th percentile on all six measures of attention, memory, and executive functioning,\n           AND has delayed sleep onset latency defined as self-report of an inability to fall\n           asleep within 30 minutes > once a week during the past month.\n\n      Within each group, participants will be randomly assigned to take either 3 mgs of time\n      release melatonin or placebo 1-2 hours before bedtime each night for 6 months.\n\n      Psychosocial measures of health-related quality of life and psychological distress will be\n      completed at baseline and following 6 months of melatonin/placebo treatment.\n\n      Biological samples for serum melatonin levels will be collected at baseline and at the 6\n      month follow-up evaluation."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  A St. Jude Life participant who was previously treated at St. Jude Children's\n             Research Hospital\n\n          -  10 or more years from diagnosis\n\n          -  18 years of age or older\n\n          -  Able to speak and understand the English language\n\n          -  Participant has a full scale intelligence quotient (FSIQ) score >79.\n\n          -  Cohort 1 participant:\n\n               -  Has neurocognitive impairment defined as performance on at least one measure of\n                  attention, memory, and/or executive functioning \u226410th percentile.\n\n               -  Is absent of delayed sleep onset latency defined as an inability to fall asleep\n                  within 30 minutes < once a week during the past month.\n\n          -  Cohort 2 participant:\n\n               -  Has neurocognitive impairment defined as performance on at least one measure of\n                  attention, memory, and/or executive functioning \u226410th percentile.\n\n               -  Has delayed sleep onset latency defined as self-report of an inability to fall\n                  asleep within 30 minutes \u2265 once a week during the past month.\n\n          -  Cohort 3 participant:\n\n               -  Is absent of neurocognitive impairment defined as performance >10th percentile\n                  on all six measures of attention, memory, and executive functioning.\n\n               -  Has delayed sleep onset latency defined as self-report of an inability to fall\n                  asleep within 30 minutes \u2265 once a week during the past month.\n\n          -  Female participant of childbearing age must not be pregnant or lactating\n\n          -  Female research participant of childbearing age and male research participant of\n             child fathering potential agrees to use safe contraceptive methods\n\n        Exclusion Criteria:\n\n          -  Known allergy to melatonin or any ingredients of the study product or placebo\n\n          -  Participant currently is taking melatonin\n\n          -  Known sleep apnea or medically treated sleep disorder (e.g. restless leg syndrome)\n\n          -  Known diabetes mellitus - insulin treated\n\n          -  Participant has uncontrolled seizure disorder in past 12 months\n\n          -  Reported current illicit drug or alcohol abuse or dependence\n\n          -  Reported current major psychiatric illness (i.e. schizophrenia, bipolar disorder)\n\n          -  Current treatment with: (1) benzodiazepines or other central nervous system\n             depressants, (2) fluvoxamine, (3) anticoagulants (e.g. coumadin), (4)\n             immunosuppressant or corticosteroids, OR (5) nifedipine (Procardia XL(R))\n\n          -  Employed in a position that requires night work (i.e. 10pm to 6am)\n\n          -  Females who are pregnant or lactating/nursing\n\n          -  History of neurologic event (i.e. traumatic brain injury) unrelated to cancer or its\n             treatment\n\n          -  Sensory impairment (vision, hearing) that prohibits completion of neurocognitive\n             examination"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "457", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 25, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01700959", 
            "org_study_id": "MIND", 
            "secondary_id": "P30CA021765"
        }, 
        "intervention": [
            {
                "arm_group_label": "Melatonin", 
                "description": "Melatonin 3mg time release will be given.  Participants will be instructed to take one 3mg time released tablet by mouth approximately 1-2 hours before initiating sleep onset, preferably at the same time each night.", 
                "intervention_name": "melatonin", 
                "intervention_type": "Drug", 
                "other_name": "N-Acetyl-5-Methoxytryptamine"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo tablets to match the melatonin will be comprised of inert substances.", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug", 
                "other_name": "placebo"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Melatonin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Melatonin", 
            "Neurocognitive impairment", 
            "Sleep disturbance", 
            "Childhood cancer survivors"
        ], 
        "lastchanged_date": "March 20, 2014", 
        "link": {
            "description": "St. Jude Children's Research Hospital", 
            "url": "http://www.stjude.org"
        }, 
        "location": {
            "contact": {
                "email": "info@stjude.org", 
                "last_name": "Tara Brinkman, PhD", 
                "phone": "866-278-5833"
            }, 
            "facility": {
                "address": {
                    "city": "Memphis", 
                    "country": "United States", 
                    "state": "Tennessee", 
                    "zip": "38105"
                }, 
                "name": "St. Jude Children's Research Hospital"
            }, 
            "investigator": {
                "last_name": "Tara Brinkman, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Melatonin Intervention For Neurocognitive Deficits in the St. Jude Lifetime Cohort", 
        "overall_contact": {
            "email": "info@stjude.org", 
            "last_name": "Tara Brinkman, PhD", 
            "phone": "866-278-5833"
        }, 
        "overall_official": {
            "affiliation": "St. Jude Children's Research Hospital", 
            "last_name": "Tara Brinkman, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Efficacy of melatonin treatment on neurocognitive functioning in adult survivors of childhood cancer (Cohorts 1 and 2).\nThe measures will be analyzed to compare change in neurocognitive performance from baseline to 6 months between active treatment and placebo groups.", 
            "measure": "Neurocognitive function as measured by performance on standardized tests of attention, memory, and executive function.", 
            "safety_issue": "No", 
            "time_frame": "Baseline and 6 months after start of therapy"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01700959"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Efficacy of melatonin on delayed sleep onset latency in long-term childhood cancer survivors (Cohorts 2 and 3).\nThe measures will be analyzed to compare change in sleep onset latency from baseline to 6 months between active treatment and placebo groups.", 
                "measure": "Sleep onset latency as measured by actigraphy and self-report.", 
                "safety_issue": "No", 
                "time_frame": "Baseline, three, and six months after start of therapy"
            }, 
            {
                "description": "Investigate whether improvement in sleep onset latency due to melatonin treatment is associated with neurocognitive improvement in long-term childhood cancer survivors (Cohort 2).\nChange in neurocognitive performance from baseline to 6 months will be examined in relation to change in sleep onset latency.", 
                "measure": "Neurocognitive function as measured by performance on standardized tests of attention, memory, and executive function, and sleep onset latency as measured by actigraphy and self-report.", 
                "safety_issue": "No", 
                "time_frame": "Baseline and six months after start of therapy"
            }
        ], 
        "source": "St. Jude Children's Research Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "St. Jude Children's Research Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}